Quick Answer
GT Biopharma, Inc. reported R&D Expense of $3.47 million for fiscal year 2025.
GT Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.47M | -40.1% |
| 2024 | $5.80M | -10.3% |
| 2023 | $6.47M | -26.6% |
| 2022 | $8.81M | -8.1% |
| 2021 | $9.59M | +1877.5% |
| 2020 | $485.0K | -70.9% |
| 2019 | $1.67M | -81.6% |
| 2018 | $9.07M | +749.0% |
| 2017 | $1.07M | +9.5% |
| 2016 | $975.0K | -2.5% |
| 2015 | $1.00M | — |
| 2014 | $0.00 | — |
| 2013 | $0.00 | — |
| 2012 | $0.00 | -100.0% |
| 2011 | $17.0K | -90.5% |
| 2010 | $179.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $634.0K | -51.5% | +74.7% |
| June 30, 2025 | $363.0K | -79.7% | -67.0% |
| March 31, 2025 | $1.10M | +41.4% | -15.9% |
| September 30, 2024 | $1.31M | -4.2% | -26.7% |
| June 30, 2024 | $1.78M | -14.8% | +129.6% |
| March 31, 2024 | $777.0K | -52.9% | -43.0% |
| September 30, 2023 | $1.36M | -50.3% | -34.9% |
| June 30, 2023 | $2.10M | +83.9% | +27.0% |
- GT Biopharma, Inc. showed a decrease of -40.1% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, GT Biopharma, Inc.’s r&d expense has grown by 1839.7% (from $179.0 thousand to $3.47 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: